Corporate Japan is steeling itself for hostile interest - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
观点 日本商业和金融

Corporate Japan is steeling itself for hostile interest

The volume of shareholder activism and dealmaking by private equity has mushroomed
00:00

{"text":[[{"start":9.12,"text":"The best advice for a Japanese chief executive right now, confides an investment banking head in Tokyo, is to plot out a move so radical that nobody imagines you would ever consider it: the sale of seemingly indispensable assets, a full break-up, a transformative deal — something that goes way beyond anything you’ve already said you will do to raise corporate value. "}],[{"start":28.810000000000002,"text":"Then put that idea in the company safe, mark it “emergency use” and keep the combination handy. "},{"start":34.302,"text":"The chances are rising that it will be needed before the end of 2025. "},{"start":38.344,"text":"Corporate Japan has been rumbled, and everyone needs a plan. "}],[{"start":42.64,"text":"The recommendation, which the banker says he has dispensed to various worried CEOs since September, caps a year in which the environment for Japanese listed companies has fundamentally changed, at a pace that few would have considered plausible as recently as 18 months ago. "},{"start":56.819,"text":"Corporate governance abuse, woeful allocation of capital and the chronic playing down of shareholder interests are much harder to hide. "},{"start":63.487,"text":"The market is newly scary in ways that include the state-sanctioned concept of “takeover without consent”. "}],[{"start":69.82,"text":"Japan will close 2024 second only to the US for shareholder activism and dealmaking by private equity. "},{"start":76.574,"text":"The escalating clash between KKR and Bain Capital over Fuji Soft is a stunning showcase of what can happen when an activist fund with a decent-sized stake decides to initiate a sale process for the whole company and private equity decides to go gladiatorial over the outcome. "}],[{"start":91.11999999999999,"text":"Mainstream investors are also being encouraged to take a tougher line on Japanese companies, and by the establishment itself. "},{"start":97.82399999999998,"text":"In November, the Tokyo Stock Exchange published an extraordinary document citing the experience of frustrated fund managers and setting out, in sometimes embarrassing detail, “cases where companies are not aligned with investors’ perspectives”. "}],[{"start":111.13999999999999,"text":"The government’s M&A guidelines were meanwhile updated in mid-2023 to encourage greater transparency by companies on offers they have received, and to propel some much overdue domestic consolidation. "},{"start":122.25699999999999,"text":"Entrenched managements cannot simply ignore approaches as they did in the past. "}],[{"start":127.27999999999999,"text":"The $47bn takeover approach by Canada’s Alimentation Couche-Tard for Japan’s biggest convenience store operator, Seven & i Holdings, has proved that no Japanese company is off limits unless national security is threatened. "},{"start":140.07199999999997,"text":"Nissan’s preliminary merger talks with Honda may well have been accelerated by the perception that a delay would have given time for a foreign buyer to pounce. "}],[{"start":148.57999999999998,"text":"While Japanese companies have fretted to their advisers about how to deal with the desk-thumping demands of an aggressive activist, how to mollify more directly critical pension funds or how to remain independent in the face of a legitimate, deep-pocketed buyer, brokers and bankers have been busily constructing lists of precisely which weakly valued, poorly governed names represent the most vulnerable targets. "}],[{"start":168.54,"text":"“Now, nobody’s safe and that’s the way it should be . . . Japan is a dirt-cheap, highly liquid, target-rich environment,” says CLSA strategist Nicholas Smith. "}],[{"start":178.34,"text":"The reality for Japanese companies, in the face of this sudden omni-challenge from activists or buyers, is that there are really only a couple of ways to reliably defend themselves. "},{"start":187.769,"text":"Some minnows may put their faith in a poison pill, some may hope that they are swaddled in the protective casing of national security. "},{"start":194.262,"text":"Everyone else just needs to be a lot more profitable and a lot more valuable than they are now. "}],[{"start":199.42000000000002,"text":"The good news is that the presence of all that private equity and its eagerness to buy (and even fight over) quality Japanese businesses mean that fate is currently providing a solution. "},{"start":208.774,"text":"Offloading non-core businesses and streamlining companies into simpler entities has never been a more available option. "}],[{"start":215.53000000000003,"text":"But not all will have time to do that before the activist, the hostile buyer or a combination of both decides to strike. "},{"start":222.09700000000004,"text":"And when they do, one of the clearest grounds for attack will be the failure of the current management to focus sufficiently on raising the company’s valuation and profitability. "},{"start":230.53900000000004,"text":"When the activists sneer at the timidity of the midterm plan, or the buyer exploits the conglomerate discount your corporate structure invites, it is time to activate the plan in the safe: a revaluation rip-cord to see off the assailant with a bold, ready-to-deploy demonstration of radical thinking. "}],[{"start":246.55000000000004,"text":"It is a fine theory and, in the very short term, good advice. "},{"start":250.76700000000005,"text":"It will not be long, though, before every investor’s first question to Japanese management is, “What have you got in the safe? ”"}],[{"start":257.63000000000005,"text":""}]],"url":"https://creatives.ftmailbox.cn/album/185658-1734593271.mp3"}

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

肺纤维化生物科技公司Avalyn Pharma申请首次公开募股(IPO)

一家生物技术公司正开发可吸入剂型的已获批肺纤维化口服药,计划赴公开市场融资以支持其后期研发。
13小时前

凯勒拉治疗学公司在生物技术领域创纪录的IPO中融资6.25亿美元

最新的生物科技公司首次公开募股创下历史新高。
1天前

法国将迎来最拥挤的大选角逐场:谁将取代马克龙?

左翼和中间阵营的分裂,助长了极右翼问鼎爱丽舍宫的希望。

全球失衡的凯恩斯式解决方案

自20世纪40年代以来,经济学家一直在提出各种方案,试图修复由国际储备货币所造成的结构性问题。

伊朗战争在多大程度上影响美国通货膨胀?

日元接下来何去何从?英国今年的经济增长是否正在回升?

华尔街顶级律师事务所如何沦为内幕交易的输送渠道

并购咨询已演变成庞大的法律业务,却让律所在机密信息被滥用方面更加脆弱。
设置字号×
最小
较小
默认
较大
最大
分享×